Kenvue Inc.
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Kirk L. Perry
- Full Time Employees
- 22,000
- Sector
- Consumer non-durables
- Industry
- Household/Personal care
- Address
- 1 Kenvue Way Summit NJ United States 07901
- IPO Date
- May 4, 2023
- CIK
- 0001944048
- Website
- kenvue.com
- Similar Companies
- Business
- Kenvue Inc. Kenvue Inc. (KVUE) operates as the world's largest pure-play consumer health company by revenue, focusing on science-backed everyday care products that serve over 1.2 billion people daily across more than 100 countries including the United States, Europe, the Middle East, Africa, Asia-Pacific, and Latin America. The company manages three core segments: Self Care, offering cough, cold and allergy remedies, pain care, digestive health, smoking cessation, eye care, and related products under brands such as Tylenol, Motrin, Benadryl, Nicorette, Zarbee’s, ORSL, Rhinocort, Calpol, and Zyrtec; Skin Health and Beauty, providing face and body care, hair, sun, and other solutions via Neutrogena, Aveeno, Dr.Ci:Labo, Le Petit Marseillais, Lubriderm, Rogaine, and OGX; and Essential Health, encompassing oral care, baby care, women’s health, wound care, and other items through Listerine, Johnson’s, Band-Aid, Stayfree, o.b., tampons, Carefree, and Desitin Diaper Rash. Incorporated in 2022 as a spin-off from Johnson & Johnson Johnson & Johnson and headquartered in Summit, New Jersey, Kenvue draws on a heritage exceeding 135 years in consumer health innovation. In November 2025, Kimberly-Clark Corporation Kimberly-Clark Corporation agreed to acquire Kenvue in a $48.7 billion cash-and-stock transaction valued at approximately $21.01 per share, representing a 33% premium to recent trading levels and creating a combined consumer health and wellness entity with projected $2.1 billion in annual synergies by 2028, subject to regulatory approvals expected in the second half of 2026. Earlier in 2025, Kenvue opened its new 290,000-square-foot global headquarters in Summit, New Jersey, featuring a 100,000-square-foot Science and Innovation Lab to consolidate operations, accelerate R&D, and enhance proximity to talent and consumers; launched the Tylenol Proactive Support supplement line for joint care; initiated the Total Quit campaign advocating tobacco and nicotine regulation; and appointed Kirk Perry as permanent CEO following a strategic review amid leadership transitions.
Company News
Kenvue to Announce Third Quarter 2026 Results on October 30, 2026
October's 5 Dividend Growth Stocks With Yields Up To 7.99%
First Citizens Bank & Trust Co. Purchases New Position in Kenvue Inc. $KVUE
Kimberly-Clark, Kenvue Win Conditional EU Approval for $40 Billion Tie-Up
Kimberly-Clark Announces Successful Consent Solicitations for Kenvue Notes and Amendment to Terms of Exchange Offers
Market Concentration Is Spooking Wall Street—I'm Buying Kenvue
NWL or KVUE: Which Is the Better Value Stock Right Now?
4 Dividend Aristocrats Still Raising Their Payouts No Matter What Their Stock Price Did
Kimberly-Clark Announces Planned Executive Transitions and Updates to Post-Closing Leadership Team
5 ‘Bulletproof’ Dividend Kings Boomers Should Buy Now Before the Market Shifts
Kimberly-Clark Pays Out Almost Everything It Earns. Can the Dividend Survive the Kenvue Deal?
Kimberly-Clark Corporation Announces Commencement of Exchange Offers and Consent Solicitations for Kenvue Notes
Burning a Hole in My Pocket
Kimberly-Clark offers remedies in bid for EU approval of Kenvue deal
5 Beaten-Down Dividend Kings Ready to Roar Back in 2027 (One Yields Over 5%)
The Moneymaxxing Crowd Will Love 5 High-Yield Dividend Stocks Under $20
Kenvue Inc. $KVUE Shares Sold by Corient Private Wealth LP
Better Dividend King to Buy and Hold: Johnson & Johnson or Kenvue?
Here's My Pick for the Smartest High-Yield Dividend Stock to Buy Right Now
Kimberly-Clark readies EU remedies in bid for Kenvue deal, sources say